Business, energy, technology, markets and global industry news from Business News Today

CRISPR

PharmaDeviceNews CRISPR
Representative image: Syntax Bio’s expanded Series A funding highlights growing investor interest in Cellgorithm-driven stem cell therapy for type 1 diabetes.
Pharma & Biotech

Syntax Bio funding boost puts pancreatic beta cell therapy closer to preclinical test

Find out how Syntax Bio’s expanded Series A could shape Cellgorithm-based beta cell therapy for type 1 diabetes.

Read More
Representative image showing cardiovascular drug research and epigenetic silencing technology, reflecting Scribe Therapeutics’ STX-1150 strategy for long-lasting LDL-C reduction after a single dose.
Pharma & Biotech

Can Scribe Therapeutics make one-dose LDL-C lowering a practical CRISPR frontier?

Find out how Scribe Therapeutics’ STX-1150 could reshape long-acting LDL-C lowering through CRISPR-based epigenetic silencing.

Read More
Representative image: Scientists analyze CRISPR gene-editing and liver-targeted cardiometabolic research data in a biotech laboratory, reflecting Scribe Therapeutics’ push to advance epigenetic silencing for durable LDL-C reduction.
Pharma & Biotech

Scribe Therapeutics brings specificity challenge into focus for CRISPR cardiometabolic drugs

CRISPR can lower cholesterol. The harder test is whether Scribe can make durability, precision, and scalability work in common disease.

Read More
Representative image of non-viral gene therapy research, showing how lipid nanoparticles, CRISPR-based editing and advanced delivery platforms are gaining attention as viral vector safety concerns reshape genetic medicine.
Features & Analysis

Can non-viral gene therapies solve the safety problem holding back genetic medicine?

Viral vectors built gene therapy’s first era. Safety, redosing and manufacturing pressure are pushing non-viral platforms into the spotlight.

Read More
Pharma & Biotech

Cathy Tie’s Origin Genomics targets germline gene correction under US IRB oversight

Origin Genomics launches in New York to advance germline gene correction and MRT under IRB oversight. Analyse what it means for US gene editing regulation.

Read More
A representative image of advanced single-cell analysis and AI-driven drug discovery workflows, reflecting Illumina’s Billion Cell Atlas initiative with AstraZeneca, Merck, and Eli Lilly to accelerate next-generation precision medicine.
Medical Devices & Diagnostics

Illumina’s Billion Cell Atlas marks inflection point for AI-enabled drug discovery in 2026

Illumina, Inc. has launched the Billion Cell Atlas, a large-scale genetic perturbation dataset designed to serve as foundational infrastructure for artificial intelligence-enabled drug discovery. Announced alongside strategic collaborations with AstraZeneca, Merck, and Eli Lilly and Company, the platform leverages CRISPR-based genome editing and single-cell RNA sequencing across more than 200 disease-relevant cell lines. This marks

Read More
Pharma & Biotech

Why Aurora Therapeutics believes the FDA is ready for grouped CRISPR approvals

Can Aurora Therapeutics make CRISPR work at scale? Find out how its platform model for rare disease editing is testing biotech’s next big leap.

Read More
Representative image. A laboratory research setting illustrating early-stage genome‑editing development, reflecting the FDA clearance allowing GenEditBio to begin its first clinical trial of GEB‑101 for TGFBI corneal dystrophy.
Pharma & Biotech

FDA gives go-ahead to GenEditBio’s first genome-editing trial for TGFBI corneal dystrophy

GenEditBio Limited, a Hong Kong–headquartered clinical-stage biotechnology firm focused on in vivo genome-editing therapies, announced that the United States Food and Drug Administration has cleared its Investigational New Drug application for GEB‑101, a CRISPR-based candidate for TGFBI corneal dystrophy. This regulatory milestone authorizes the launch of the Phase 1/2 CLARITY trial in the United States,

Read More